🇺🇸

US SEC Filing Intelligence

· daily

Dow Jones 30 Stocks SEC Filings — March 04, 2026

Across 121 SEC filings from diverse US companies (despite DJ30 focus, spanning retail, healthcare, energy, tech, and industrials), overarching themes include mixed financial results with 22/45 quantifiable revenue reporters showing YoY growth averaging +15% (e.g., Republic Airways +20.6%, Veeva +16%), but 12 experiencing declines averaging -8% (e.g., Cracker Barrel -7.9%, Bath & Body Works -2%), driven by margin compression in retail (-150bps avg in 5 cos) and consumer weakness offset by M&A-fueled gains. Capital allocation leans bullish with 9 share repurchase programs (e.g., Innovative $100M, National Vision $50M renewed), debt reductions (e.g., Republic $231.6M repaid), and dividends maintained/raised (e.g., Global Water $0.30396 annualized), signaling management conviction amid 15 guidance issuances mostly maintained/raised for 2026. Insider activity is sparse but positive where noted (e.g., no major sales); M&A/divestitures active in 12 filings (e.g., Ziff Davis sale to Accenture, Diversified Energy $245M acquisition). Critical developments: 2 bankruptcies/delistings (Charles & Colvard Ch11, Vicarious NYSE delisting), but portfolio-level trends show improving cash flows (15/25 with data up YoY) and backlog growth (e.g., Orion +470% implied via Babcock). Implications: Rotate to growth sectors like healthcare/tech (avg +12% revenue) from retail; monitor Q1 2026 catalysts for alpha.

65 high priority 56 medium 121 total filings
· daily

US SEC Filings Daily Market Digest — March 04, 2026

Across 433 SEC filings for March 4, 2026, mixed sentiment prevails with 60% of 10-Ks showing revenue growth (avg +12% YoY) but frequent margin compression (-120 bps avg in consumer/retail) and widened losses in 45% of cases, driven by SG&A surges (+25% avg YoY) and impairments. Consumer-facing firms like Kontoor Brands (+21% revenue YoY via acquisitions) and National Vision (+9% revenue, +56% adj op income) outperform, while energy producers like Gran Tierra (+32% production YoY but -23% EBITDA) and Xponential Fitness (flat SSS, -2% revenue) lag amid cost pressures. Capital allocation leans shareholder-friendly with buybacks/dividends in 25% of filings (e.g., Kontoor $25M remaining auth, News Corp $1B program), but dilution risks rise (US Energy 19% new shares). M&A/divestitures active (SSR Mining $1.5B sale, Ziff Davis asset sale), SPAC/de-SPAC momentum builds (Pelican, Haymaker), and financing abundant (Applied Digital $2.15B notes). Forward guidance cautious but positive in healthcare/tech (National Vision $107-133M adj op inc FY26). Portfolio trend: Rotate to margin-resilient growth (e.g., Cricut +26% op income) away from cyclical retail/energy.

215 high priority 218 medium 433 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 04, 2026

Across 69 filings from S&P 500 Consumer Discretionary and adjacent sectors, overarching themes include mixed revenue growth with top-line expansion in 7/15 retail/fitness firms (avg +10% YoY, e.g., Black Rock Coffee +24.5%, Abercrombie +6%) offset by widespread margin compression (avg -150bps across 9 reporters) and operational losses; capital returns remain robust with buybacks/dividends in 8 firms (e.g., Abercrombie $450M repurchase, Brown-Forman $400M). M&A/divestitures active (Ziff Davis sale to Accenture, Farmer Bros acquisition at $1.29/share), alongside leadership transitions signaling AI/strategic pivots (FactSet AI officers). Period-over-period trends show YoY revenue growth in 12/25 quantified filers (+avg 8%) but net income declines in 10/20 (-avg 25%), with forward guidance cautious (e.g., Abercrombie 3-5% sales growth FY26). Portfolio-level patterns flag consumer resilience in apparel/restaurants but vulnerability in fitness/specialty retail amid cost pressures; actionable now: prioritize buyback-heavy names pre-AGMs.

38 high priority 31 medium 69 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 04, 2026

Across 30 filings in the USA S&P 500 Healthcare stream (with broader financial/REIT inclusions), dominant themes include clinical progress in biotech/oncology (Citius 86% ORR Phase 1, Cellectar Q3 2026 EMA submission) offsetting cash burns (-43% at Cellectar to $13.2M), mixed revenue trends (Niagen +30% YoY to $129.4M, Sight Sciences -3% to $77.4M), and strong financial recoveries (Bankwell net income +260% YoY to $35.2M, First Financial +67.5% to $79.2M). Period-over-period highlights: NII surges avg +50% YoY in banks (Alerus +61.1%), provisions down sharply (Bankwell -95%), but deposits -3-4% across lenders and op ex rises (Niagen Q4 +59%). Capital allocation shows dividend hikes (First Financial to $2.04/share) vs constrained buybacks (Procaccianti prorated 3.6%). Forward-looking catalysts cluster mid-2026 (Cellectar Phase 1b data, Sight Sciences 6-14% revenue growth to $82-88M). No insider buys/sells detailed, but director resignations (MVB over governance) flag concerns. Implications: Bullish oncology combos and bank turnarounds; bearish dilution/funding risks in biotechs; monitor 2026 guidance execution for alpha.

12 high priority 18 medium 30 total filings
· daily

Global High-Priority Regulatory Events — March 04, 2026

Across 237 filings in the Global High Priority Market Events stream (US SEC focus, March 4, 2026), dominant themes include debt refinancings (e.g., Cooper-Standard $1.1B lower-cost notes), M&A/divestitures (SSR Mining $1.5B sale, Ziff Davis to Accenture), and distress signals like bankruptcies (Charles & Colvard Chapter 11) and insolvencies (TV Vision ₹294Cr petition). Period-over-period trends show mixed revenue growth (avg +8% YoY in reporting 10-Ks like National Vision +9%, Kontoor +21%, but declines in Xponential -2%, Sensus -34%) with widespread margin compression (e.g., 6/12 consumer firms -100-200bps avg due to SG&A rises) offset by cost savings in refinancings. Insider activity sparse but positive (Bondada promoter +0.003% stake), capital allocation leans to buybacks/dividends (Kontoor $25M remaining, Horizon $0.18 Q2 2026), while forward guidance highlights AI catalysts (Alnylam 2029 vesting at $500-800 stock price). Portfolio-level patterns flag energy/mining outperformance (Gran Tierra prod +38% YoY) vs retail weakness (Cracker Barrel rev -7.9% QoQ), with regulatory fines (BF Utilities ₹5.43L) and delistings (Vicarious NYSE suspension) amplifying volatility. Implications: Opportunistic buys in refinanced industrials, avoid distress names; monitor Q1 earnings for margin recovery.

237 high priority 237 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 04, 2026

The IPO Pipeline stream features a single S-1 filing from Transglobal Management Group, Inc. (TMGI), formerly Marquie Group, Inc., a Florida-based radio broadcasting company registering securities for a potential public offering on March 4, 2026. Balance sheets are disclosed for fiscal years ending May 31, 2023, 2024, and 2025, indicating multi-year financial tracking amid extensive related-party transactions (payables to CEO's wife and mother) and numerous notes payable/convertible notes, with no specific revenue or net income metrics provided. Neutral sentiment reflects operational complexity without overt bullish or bearish indicators, but high materiality (8/10) underscores significance for IPO trackers. Period-over-period balance sheet disclosures suggest stability sufficient for IPO pursuit, though heavy debt and related-party exposure signal governance risks in the radio sector. Key implications include potential new public float for liquidity-seeking investors, dilution risks from convertibles, and a catalyst for monitoring SEC review process in a niche media IPO landscape.

1 high priority 1 total filings
· daily

US Earnings Financial Results SEC Filings — March 04, 2026

Across 74 SEC filings primarily 10-Ks for FY2025, US companies showed mixed financial results with 42/74 reporting revenue growth (avg +12% YoY where specified), but 51/74 had net losses or widened losses, driven by impairments (e.g., Grocery Outlet $149M goodwill, Oil States $100M), margin compression (avg -150bps in 28 cos), and rising SG&A (up avg 15% in 35 cos). Energy firms like Gran Tierra (-30% prices, $136M impairment) and Ring Energy (negative gas prices) faced commodity headwinds, while finance (e.g., First Financial NII +25.6%, Unity ROA 2.17%) and select biotech (Keros revenue +6772%, SCYNEXIS +450%) outperformed. Capital allocation leaned defensive with buybacks (e.g., Kontoor $25M, Daktronics $22.8M) and dividends steady, but debt reductions (Oil States to $1.7M) signal deleveraging. Portfolio trends highlight retail weakness (comp sales flat/-5% avg in 5 cos) vs. resilience in niche growth like Red Violet (+20% rev). Implications: Favor financials/biotech turnarounds, avoid energy/retail amid cost pressures; watch Q1 2026 earnings for guidance updates.

74 high priority 74 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 04, 2026

Across 21 DEF 14A proxy statements filed around March 4, 2026, the dominant theme is preparation for Q2 2026 annual/special meetings focused on director elections (one-year or staggered terms), advisory say-on-pay votes, and auditor ratifications, reflecting stable governance amid no reported financial declines or period-over-period metric deteriorations. High board independence prevails (e.g., 11/12 at Texas Instruments, 100% independent committees at Xperi), with >75% attendance rates standard (Select Medical 8 meetings FY2025, iPower 3 meetings +5 consents YE6/30/25), signaling strong alignment. Closed-end funds (8/21, Nuveen cluster) cluster elections on April 16 with neutral sentiment/low materiality (5-6/10); operating companies show governance tweaks like declassification (Select Medical), CEO transitions (A.O. Smith), and combined Chair/CEO (CenterPoint). Mixed sentiments in Celanese (strategic transformation post-Micromax divestiture) and Goldenstone SPAC (extension vote risks liquidation, trust $5.77M at 12/31/25 ~$13.03/share redemption vs $11.51 close). No insider trading, capital allocation, or YoY financial trends reported, but upcoming comp votes and pay-vs-performance disclosures (MYR, H.B. Fuller XBRL PEO/NEO adjustments FY21-25) offer alignment insights. Portfolio implications: monitor April meeting outcomes for say-on-pay pass rates as comp conviction proxy; SPAC/special proposals flag distress opportunities.

21 high priority 21 total filings
· daily

US Executive Officer Management Changes SEC — March 04, 2026

Across 29 US SEC filings on executive and director changes from March 4, 2026, overarching themes include routine retirements and appointments (17 neutral), strategic hires in AI/tech/biotech (positive sentiment in 6), and concerning departures (negative in 4), with mixed financial updates in high-materiality filings like BillionToOne's 100% FY2025 revenue growth and National Presto's 29.7% sales rise offset by 20.2% earnings drop. Period-over-period trends reveal strong growth outliers (BillionToOne +113% Q4 revenue YoY, oncology +735%) amid margin expansions (e.g., 68% FY gross margin vs 53% prior), but pockets of decline like Clinical Trial revenues -18% YoY. Positive capital allocation signals include National Presto's unbroken 82-year dividend ($1.00/share, record Mar 9) and Alnylam's CEO performance award tied to 54-146% stock price upside by 2029. Portfolio-level patterns show financials/banks with board reductions/resignations (WesBanco -4 directors, MVB governance dispute), signaling potential governance risks, while biotech/health firms emphasize experienced hires for pivots (Tivic CEO, FactSet AI roles). Market implications favor innovation-driven leadership continuity for alpha, with watch for succession voids in finance.

29 high priority 29 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — March 04, 2026

Across 45 filings in the USA Corporate Distress & Bankruptcy stream, the dominant theme is proactive debt management and refinancing (seen in 20+ filings like Alliant Energy's $400M credit, Cooper-Standard's $1.1B notes at lower 9.25% vs prior 13.5%), signaling stabilization efforts amid isolated acute distress (1 bankruptcy, 1 delisting). Period-over-period trends where available show mixed revenue (Babcock & Wilcox flat Q4 YoY at $161M, Smith Micro -20% Q4/-16% FY2025 YoY, Aquestive +10% Q4 but -3% FY), but improving profitability (Babcock Adj EBITDA +53% Q4/+107% FY, Smith Micro net losses narrowed FY $30.1M from $48.7M). Capital allocation leans toward deleveraging (Sabre redeemed $91.6M notes, Franklin Street refinanced $320M at 9%), with M&A/divestitures (SSR Mining $1.5B mine sale, Farmer Brothers $1.29/share acquisition) providing liquidity. Forward-looking catalysts include Q3 2026 deal closes (SSR, Farmer) and earnings (Babcock 3/16), while portfolio-level patterns reveal energy/healthcare leading refinancings but tech/microcaps highest distress (delistings, bankruptcies). Overall, implies bottoming distress with recovery potential for refinanced names, but speculative trading risks in bankrupt/delisted firms.

45 high priority 45 total filings
· daily

US SEC Trading Suspension Halt Orders — March 04, 2026

The single filing in the USA Trading Suspensions stream highlights Vicarious Surgical Inc. (RBOT), where NYSE suspended trading on March 3, 2026, due to average global market capitalization falling below the $15M threshold over a consecutive 30 trading day period under Section 802.01B, triggering delisting proceedings via Form 25 post-appeal. No period-over-period financial trends, revenue growth, or margin improvements were reported, underscoring sustained underperformance with no positive metrics. The company is evaluating an appeal within 10 business days, while gaining OTCID quotation approval starting March 4, 2026, but this shift anticipates depressed stock prices, reduced liquidity, limited equity financing, and impaired employee incentives. Market implications include heightened volatility, illiquidity risks, and potential for further downside in small-cap medtech names facing listing challenges. Portfolio-level pattern: isolated but emblematic of small-cap distress amid low market caps, signaling broader caution for thinly traded US equities on major exchanges.

1 high priority 1 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — March 04, 2026

Charles & Colvard Ltd's voluntary Chapter 11 bankruptcy filing on March 2, 2026, represents the sole but highly material event in the USA Bankruptcy & Insolvency stream, signaling acute corporate distress with no offsetting positive developments across the filing. While specific period-over-period financial comparisons are not detailed, the petition implies prolonged liquidity pressures culminating in insolvency, with the company operating as a debtor-in-possession (DIP) and seeking first-day relief for critical payments like employee wages, vendors, insurance, and taxes. Potential defaults under the June 24, 2025 Convertible Secured Note with Ethara Capital LLC and lease with SBP Office Owner, L.P., could accelerate obligations, though stayed by bankruptcy law. Equity trading is deemed highly speculative, with shareholders at risk of significant or complete loss depending on restructuring outcomes. This filing underscores portfolio-level risks in distressed names, advising immediate equity avoidance and monitoring for creditor recoveries or asset sales. Negative sentiment dominates at 10/10 materiality, with no bullish insider activity, capital allocation, or guidance changes evident.

1 high priority 1 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 04, 2026

Across 29 US SEC filings on boardroom changes from March 4, 2026, a surge in C-suite and director transitions highlights proactive succession planning in tech/AI (FactSet), biotech/health (Tivic, BillionToOne, RemSleep), and packaging (Crown), contrasted by retirements and resignations in financials (AmeriServ, Johnson Outdoors, MVB, WesBanco). Period-over-period trends show robust growth outliers like BillionToOne's Q4 2025 revenue +113% YoY ($96.1M) and FY +100% ($305.1M) with gross margins expanding to 71% Q4/68% FY from 57%/53%, and National Presto's defense sales +42.9% YoY ($121.9M increase), though offset by housewares declines -7% and net earnings -20.2%. Forward-looking catalysts include raised 2026 revenue guidance at BillionToOne ($430-445M, +41-46%), Alnylam's stock price vesting targets ($500-800 by late 2029), and dividend record dates (Presto March 9). Capital allocation leans toward equity incentives (Alnylam $18M award, RemSleep 7% equity) vs. modest dividends (Presto $1.00/share). Portfolio implications: Bullish for AI/biotech pivots amid experienced hires, bearish governance risks in financials; monitor Q1 earnings for transition impacts.

29 high priority 29 total filings
· daily

US Merger & Acquisition SEC Filings — March 04, 2026

Across 11 US SEC filings on March 3-4, 2026, M&A and takeover activity surges with 5 SPAC-related updates (mergers advancing, IPOs, PFIC statements), 3 major acquisitions ($2.7B CMCO, $450k Invech, Ventyx change-in-control), and 3 divestitures ($50.1M SITE, snacks HAIN, $210M CMCO) focused on debt reduction and portfolio sharpening. Positive sentiment prevails in 5/11 filings (45%), neutral in 5, signaling strategic execution amid no broad period-over-period declines reported; pro forma data in CMCO reflects post-deal leverage without synergies quantified. Key themes: SPAC de-risking via warrant exchanges/support (Haymaker 49.8% holders), debt-financed growth (CMCO $3.35B facilities), and non-core asset sales boosting liquidity (HAIN focuses on higher-margin yogurt/tea). Market implications include M&A arbitrage potential in SPACs, deleveraging tailwinds for consumer/industrials, and watch for dilution from convertibles/preferreds. No insider trading or explicit YoY/QoQ trends across filings, but forward-looking catalysts like warrant meetings and note maturities loom. Portfolio-level pattern: 7/11 filings advance deals without red flags on metrics, favoring tactical longs in completers.

11 high priority 11 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 04, 2026

Overnight SEC filings reveal a mixed but resilient US equity landscape, with precious metals ETFs (abrdn Gold, Silver, Platinum, Palladium, Precious Metals Basket) posting explosive YoY asset growth averaging 150-280% driven by metal price surges, contrasting margin compression and revenue declines in industrials (Eastern Co -190bps gross margin, HYSTER-YALE -12.5% revenue to net loss) and consumer (B&G Foods divestitures, Versant Media -5.3% revenue). BDCs and credit funds show portfolio expansion (e.g., 92-313 companies +43-109% commitments) but uniform yield declines to 8.5-9.2% from 9.5-10.2% amid rising leverage (5.7-6.3x), signaling caution in private credit. Tech outliers shine (Credo Technology +202% Q3 revenue to $407M, 68.5% margins), while biotech/pharma mixed with revenue volatility (Evolus +11.6%, Arcturus -46%). Governance filings dominate (50+ Nuveen DEF 14A for April 16 meetings, record dates Feb 9), neutral but highlighting virtual AGMs; SPACs (Pono, Cortigent) eye IPOs with dilution risks. Capital returns steady (buybacks/dividends in Copart, Superior Group), but restatements (ABVC revenue erased) and bankruptcies (Charles & Colvard Ch11) flag micro-cap distress. Portfolio trend: 40% positive sentiment in metals/resources, 30% mixed industrials/BDCs, implying rotation to commodities pre-market.

162 high priority 101 medium 263 total filings
· daily

Biotech Small-Cap Approvals — March 03, 2026

This period's 19 biotech small-cap approvals were overwhelmingly neutral (18/19), consisting of routine ANDA generic entries under standard review with no special designations, signaling portfolio expansions for generics-focused sponsors amid pricing pressures. One bullish original NDA for Eton Pharmaceuticals' DESMODA stands out as the sole innovative signal in a sea of commoditized generics. No high-impact catalysts emerged, emphasizing steady but low-margin growth over breakthroughs for small-cap biotech investors.

19 total filings
· daily

New Drug Approvals (Original) — March 03, 2026

This one-day snapshot captures 19 original drug approvals from late February 2026, overwhelmingly generic ANDAs (18/19) under standard review with no special designations, signaling routine portfolio expansions for generics-focused sponsors amid competitive pricing pressures. The lone NDA approval for Eton Pharmaceuticals' desmopressin acetate provides the period's only bullish signal, potentially diversifying its portfolio beyond generics norms. Absence of therapeutic areas/indications across most records limits market sizing, emphasizing commoditized generics momentum over innovative breakthroughs.

19 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 03, 2026

Across 34 filings in the USA S&P 500 Consumer Staples intelligence stream (broadly encompassing food, beverages, household, and personal care with some adjacent), key themes include robust revenue growth in reporting companies averaging +29% YoY for Q4 2025 (Rigel +41%, Kontoor +46%, Fuel Tech +37%, Accel +7.5%), margin expansions in high performers (Accel EBITDA +18.9% YoY Q4, Fuel Tech gross +44.6%), and active M&A with premiums (Select Medical 18-25%, Diamond Hill merger approved). Leadership transitions were prevalent and largely positive (Wyndham CFO appt with outlook reaffirm, Massimo CFO, Energy Fuels smooth CEO succession), alongside capital allocation via buybacks (CCEP repurchased 749k shares), debt repayments (Haemonetics $300M full payoff), and equity facilities (PMGC $7.5M prepaid purchase). Forward-looking catalysts cluster in Q2 2026 (mergers, spin-offs), with positive guidance where provided (Rigel $275-290M 2026 rev, Kontoor +9% rev/+15% EPS). Portfolio-level patterns show 6/10 earnings reporters beating YoY revenue trends despite isolated declines (Accel Illinois -2.5% locations), signaling resilient consumer demand but mixed regional/segment performance; sentiment leans positive (14/34 positive/mixed bullish). Risks include softening pricing (SmartStop web rates -13.3% YoY Jan 2026) and M&A execution hurdles, presenting alpha via arb plays and growth outliers.

15 high priority 19 medium 34 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 03, 2026

Across 56 SEC filings from the USA S&P 500 Industrials stream (broadly including adjacent sectors like pharma/biotech due to filing mix), overarching themes include robust revenue growth in 18/56 companies averaging +22% YoY (e.g., Limbach +24.7%, Rigel +60% FY product sales), offset by margin compression in 9/56 (avg -150 bps, e.g., Limbach gross margin -160 bps) and mixed EBITDA trends (up in 12, down in 8). Capital allocation leans shareholder-friendly with buybacks (Limbach $50M program) and debt refinancings lowering costs (Adtalem -50 bps margins, Howmet $1.2B notes for acquisition). Forward-looking catalysts cluster in H1-H2 2026: 7 guidances raised/issued (e.g., Limbach $730-760M rev), 5 trial readouts (Amylyx Q3, Karyopharm mid-2026), Honeywell Aerospace spin-off progress, and M&A closes (Howmet CAM by 2026). Industrials-specific patterns show M&A/outperformance (Howmet $1.8B deal, Limbach ODR +40.6%), while pharma dominates positive pipeline (MIRA Phase 1 success, Rigel R289 H2 data). Portfolio implications: overweight growth industrials/services amid resilient demand, monitor pharma trial risks; no broad insider selling detected, but repurchases signal conviction in 3 firms.

21 high priority 35 medium 56 total filings